.jpg "H.C. Wainwright Reaffirms Their Buy Rating on Capricor Therapeutics")
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics (NASDAQ: CAPR), with a price target of $8.60. The company’s shares closed yesterday at $1.33.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -12.8% and a 34.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.60.
See today’s analyst top recommended stocks >>
Based on Capricor Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $12.31 million. In comparison, last year the company had a GAAP net loss of $3.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.
Read More on CAPR:
